These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16365271)

  • 1. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept.
    Strober BE
    Arch Dermatol; 2005 Dec; 141(12):1602. PubMed ID: 16365271
    [No Abstract]   [Full Text] [Related]  

  • 2. Alefacept treatment for chronic plaque psoriasis.
    Dunn LK; Feldman SR
    Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of palmoplantar psoriasis with intramuscular alefacept.
    Myers W; Christiansen L; Gottlieb AB
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
    Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
    J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
    Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
    J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
    Körver JE; Langewouters AM; Van De Kerkhof PC; Pasch MC
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1252-5. PubMed ID: 17062041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
    Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
    J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.
    Legat FJ; Hofer A; Wackernagel A; Salmhofer W; Quehenberger F; Kerl H; Wolf P
    Arch Dermatol; 2007 Aug; 143(8):1016-22. PubMed ID: 17709660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on alefacept safety.
    Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy outcomes in patients using alefacept in the AWARE study.
    Landells I; Searles G; Bissonnette R; Shear NH; Vender R; Lui H
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S122-30. PubMed ID: 20053324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.
    Searles G; Bissonnette R; Landells I; Shear NH; Papp K; Lui H
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S131-8. PubMed ID: 20053325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
    Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
    J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.
    Searles G; Bissonnette R; Landells I; Shear NH
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S148-52. PubMed ID: 20053327
    [No Abstract]   [Full Text] [Related]  

  • 15. The AWARE study: methodology and baseline characteristics.
    Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
    Feldman SR; Menter A; Koo JY
    Br J Dermatol; 2004 Feb; 150(2):317-26. PubMed ID: 14996104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series.
    Shah A; O'Neill J; Feldman SR
    J Drugs Dermatol; 2010 Dec; 9(12):1491-4. PubMed ID: 21120256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
    Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
    J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.